Abstract:Background There is no consensus on the beneficiary population, regimen selection, and efficacy evaluation of neoadjuvant therapy for locally advanced gastric cancer. Existing evidence shows that neoadjuvant chemoradiotherapy can increase pCR, reduce tumor staging, and improve R0 resection rate for locally advanced gastric cancer. However, due to the insufficiently high pCR and survival benefits, there is an urgent need for more effective neoadjuvant treatment regimens to improve patient outcomes. Immune checkpoint inhibitor (ICI) combined with chemotherapy has become a standard first-line treatment for gastroesophageal junction adenocarcinoma (GEJ) and gastric adenocarcinoma. In addition, radiotherapy combined with ICI may enhance the efficacy of immunotherapy. Preliminary studies have shown that short-course radiotherapy combined with ICIs and chemotherapy for neoadjuvant treatment of colorectal cancer has good efficacy and safety. Envafolimab is the world's first approved novel subcutaneously injectable PD-L1 inhibitor, which can significantly improve treatment convenience and compliance, and has shown good efficacy in multiple solid tumors including gastric cancer, small cell lung cancer, and liver cancer. The purpose of this study is to explore the efficacy and safety of short-course radiotherapy combined with envafolimab, recombinant human vascular endothelial inhibitor, and SOX regimen for neo-adjuvant treatment of resectable locally advanced gastric/gastroesophageal junction adenocarcinoma. Methods This study is a prospective, single-arm, phase II clinical trial (NCT05387681). The study plans to recruit 35 newly diagnosed patients with locally advanced gastric/gastroesophageal junction adenocarcinoma (aged 18–75 years; cT2–4aN+ M0; ECOG score ≤1). Patients who meet the inclusion criteria will receive preoperative short-course radiotherapy according to the study plan, with a tumor dose of 25Gy (5Gy/day × 5 days, from day 1 to day 5). After a one-week rest, they will receive three cycles of enovolimab (300 mg/dose, Q3W, subcutaneous injection) combined with recombinant human vascular endothelial inhibitor (210 mg, Q3W, intravenous pump infusion, given on the first three days of each cycle), and SOX regimen treatment. Radical surgery will be performed 2–4 weeks after the completion of the last neoadjuvant treatment, and adjuvant therapy will be administered based on staging, followed by survival follow-up. The primary endpoint of the study is the pathological complete response rate(pCR), and the secondary endpoints include R0 resection rate, major pathological response (MPR), and safety. Trial Registration This study for ClinicalTrials.gov identifier (NCT number): NCT05387681 Ethics Approval This study has been approved by the Medical Ethics Committee of the Union Hospital Tongji Medical College Huazhong University of Science and Technology, with review number UHCT-IEC-SOP-016–03-03. Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Sintilimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel regimen as neoadjuvant therapy for resectable gastric cancer and biomarker exploration.

Sintilimab Plus Oxaliplatin/capecitabine (capeox) As Neoadjuvant Therapy in Patients with Locally Advanced, Resectable Gastric (g)/esophagogastric Junction (GEJ) Adenocarcinoma.

Efficacy and Safety of Sintilimab in Combination with XELOX in First-Line Gastric or Gastroesophageal Junction Carcinoma (GC/GEJC)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer

The Safety and Efficacy of Immune Checkpoint Inhibitor in Combination with FOLFOX As Neoadjuvant/adjuvant Therapy in Patients with Locally Advanced Colon Cancer.

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study

Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study

Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial.

A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric cancer.

Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial

Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial

Comprehensive multi‐omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single‐center, open‐label, single‐arm phase II trial

Exploration of Neoadjuvant Chemotherapy and Post-Tumor Microenvironment for Advanced Gastric Cancer (GC) or Gastroesophageal Junction Cancer (EGJ).

Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis

Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer

658 Preoperative Short Course Radiotherapy with Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric

Preoperative Nivolumab Plus SOX in Patients with Locally Advanced Gastric or Gastro-Esophageal Junction Cancer: A Phase 2, Single-Arm Trial.

Evaluation of ctDNA in Predicting Response to Neoadjuvant Therapy and Analysis of Residual Disease in Local Advanced Gastric Cancer: Protocol of A Single-Arm Multicenter Prospective Observational Study

Immuno-based conversion therapy for survival in initially unresectable locally advanced or oligometastatic gastric cancer: A retrospective real-world study with multi-omics analysis.